News

"Receiving orphan drug status in the EU is another encouraging step in the development of RE-024 for the treatment of PKAN," said Alvin Shih, M.D., executive vice president

This filing will add important new clinical data to the current label from two Phase 3 trials evaluating the safety and efficacy of AVYCAZ, in combination with metronidazole,

Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Data from the study support the advancement of cabotegravir, an integrase strand transfer inhibitor,

The latest round of funding brings Rani Therapeutics’ total investment to over $70m. Other investors in the round were Virtus Inspire Ventures and Ping An Ventures. The company’s

The 60 year-old, from the University Of Michigan Frankel Cardiovascular Center, is one of the busiest mitral valve surgeons in the country fixing faulty heart valves when he

Lightspeed Venture Partners and Sutter Hill Ventures led the round with participation from Clarus Ventures and GV (formerly Google Ventures). Forty Seven has also licensed the rights from

The research project will assess the feasibility of using a novel, patent-pending lymph directing drug delivery technology. The technology was developed by researchers at the ARC Centre of

At Week 48, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens, based on percentages of patients with HIV-1 RNA levels less than 50

University of Washington, the Seattle Cancer Care Alliance (SCCA), Fred Hutch, and Juno are all investing in the CTU, and Juno will also provide research funds to Fred